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DĞŶƚĂů/ůůŶĞƐƐ P^ǇƐƚĞŵĂƚŝĐZĞǀŝĞǁ 
 
Christoph Kronenberg, Tim Doran, Maria Goddard, Tony Kendrick,  
Simon Gilbody, Ceri Dare, Lauren Aylott, Rowena Jacobs  
 
Abstract 
 
Background  ? Serious mental illness (SMI)  ? which comprises long term conditions such as 
schizophrenia, bipolar disorder and other psychoses  ? has enormous costs for both patients and 
society. In many countries, people with SMI are treated solely in primary care, and have particular 
needs for physical care.  
Aim - The objective of this study was to review systematically the literature to create a list of quality 
indicators relevant to patients with SMI which could be captured using routine data, and which 
could be used to monitor or incentivise better quality primary care.  
Design and setting  ? A systematic literature review, combined with a search of quality indicator 
databases and guidelines. 
Methods  ? We assessed whether indicators could be measured from routine data and the quality of 
the evidence. 
Results  ? 1,847 papers and quality indicator databases were identified, 27 were included, from 
which 59 quality indicators were identified, covering six domains. Of the 59 indicators, 52 could be 
assessed using routine data. The evidence base underpinning these indicators was relatively weak, 
and was primarily based on expert opinion rather than trial evidence. 
Conclusions  ? With appropriate adaptation for different contexts, and in line with relative 
responsibilities of primary and secondary care, use of the quality indicators has the potential to 
improve care and to improve the physical and mental health of people with SMI. However, before 
the indicators can be used to monitor or incentivise primary care quality, more robust links need to 
be established with improved patient outcomes.  
 
(243/250 words) 
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How this fits in 
This is a first systematic review of indicators of primary care quality for patients with serious mental 
illness (SMI). Our study identifies 59 quality indicators in six domains, the majority of which could be 
monitored using routine primary care data. A key domain is the focus on physical health care. 
Consideration of the use of a broad set of quality of care indicators may support the improvement of 
the mental and physical health for this patient group. 
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Introduction 
Serious mental illness (SMI) includes schizophrenia, bipolar disorder and other psychoses, (defined 
by International Classification of Diseases (ICD-10) 
1
 categories F20-F31, and including Schizophrenia 
Spectrum and Other Psychotic Disorders together with Bipolar and Related Disorders in DSM-5 
2
). 
SMI is linked with poor health outcomes, high healthcare costs and high disease burden 
3,4
. People 
with SMI have on average a 20-year lower life expectancy, mostly due to preventable causes 
5-8
. The 
global morbidity study attributed 3.5% of total Years Lost to Disability to schizophrenia and bipolar 
disorder combined 
9
. SMI is also associated with increased treatment costs 
10
 and hospitalisations. 
Yet, around a third of people with SMI in the UK are treated solely in primary care 
11
 and are in long-
term contact with primary care services more often than the general population 
12,13
. Even in 
countries with very well developed secondary mental health care systems, primary care can make a 
key contribution to the care of people with SMI 
14
. The quality of primary care of people with mental 
health problems is therefore of international concern 
15,16
. 
In the UK, a national pay-for-performance scheme, the Quality and Outcomes Framework (QOF), 
exists to financially reward family practices for achieving quality targets for patients with long term 
conditions. The SMI quality indicators in the QOF cover both mental health specific care (e.g. 
monitoring lithium levels) as well as more general physical care (e.g. routine health checks). QOF 
indicators are for high-priority disease areas for which primary care has principal responsibility for 
ongoing care, and where there is good evidence that improved primary care will have health 
benefits. However, the QOF may neglect important unmeasured aspects of quality of care 
17
, and the 
incentives may result in tunnel vision 
18
 or a focus on activities which are prioritised at the expense 
of other non-incentivised activities 
19,20
. For example, the QOF focuses more on physical rather than 
mental health, since this is generally easier to measure.  
We performed a systematic review of the literature and interrogated international databases to 
identify potential quality indicators that could supplement or replace indicators already included in 
the QOF for people with SMI and which could potentially be incentivised in primary care. We 
included indicators that appeared in earlier versions of the QOF but were subsequently dropped 
from the scheme when it was reduced in scope to reduce workload. We have included these 
indicators on the grounds that they remain valid measures of quality of care, and continue to be 
included in the broader National Institute for Health and Care Excellence (NICE) indicators menu. A 
major focus of our analysis was the source of the data on which the indicators were based. Those 
requiring primary data collection, for example via surveys of patients or health professionals or 
retrospective auditing of patient records, would be very challenging to incorporate into incentive 
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schemes such as the QOF, whereas those based on routinely available data would in principle be 
more feasible to establish.  
Previous literature reviews on quality indicators have focused on SMI in secondary care 
21,22
, while 
our study is the first to focus specifically on people with SMI in primary care.  Identifying indicators 
of primary care quality for people with SMI could help to strengthen the evidence base and shed 
light on neglected areas of care, as well as providing the basis for incentive schemes aimed at 
improving quality. 
Methods 
A systematic review of primary care quality indicators for people with SMI was conducted with the 
aim of identifying quality indicators in addition to those already included in the QOF, either in the 
past or currently. 
Inclusion and Exclusion Criteria 
We searched for published examples of potential quality indicators which could readily be collected 
in primary care with reference to routine data. Search terms were identified by an information 
specialist in conjunction with the project team. Included papers had the terms: serious mental illness 
AND primary care AND quality indicator, including alternative spellings and synonyms. Studies on 
children or covering non-psychotic illnesses e.g. severe depression or anxiety disorders were 
excluded. All studies from January 1990 to February 2015 were considered for inclusion. No 
language restrictions were applied, though all search terms were in English, and all studies in English, 
German, Dutch and Afrikaans were considered ĚƵĞƚŽĂƵƚŚŽƌƐ ?ůĂŶŐƵĂŐĞŬŶŽǁůĞĚŐĞ. The base search 
was constructed using MEDLINE and adapted to the other resources. The following databases were 
searched: Applied Social Sciences Index and Abstracts (ASSIA); CENTRAL, Cochrane Database of 
Systematic Reviews; Conference Proceedings Citation Index- Science (CPCI-S); Database of Abstracts 
of Reviews of Effects, DARE; EMBASE; Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 
and Ovid MEDLINE(R); PsycINFO and MEDLINE. The full strategy for MEDLINE as a template is 
available in Appendix 1. 
Additionally, previous reviews with overlapping aims were searched and we contacted authors to 
ask for their indicators (most notably Stegbauer et al 
21
 and Gro¡imlinghaus et al 23). The quality 
indicator database of the Agency for Healthcare Research and Quality (AHRQ) 
24
 was also searched 
for indicators relevant to primary care. The final selection of indicators was informed by the views of 
our Study Steering Committee, which included service users. 
6 
 
Study Selection 
Titles were first reviewed by MG, TK, TD, RJ and CK. All studies that two members of the research 
team indicated as potentially relevant were included in the abstract screening process. All abstracts 
were screened by LA, MG, TK, TD, RJ and CK, and full papers were obtained if two members of the 
team judged the abstract potentially relevant or in scope, i.e. covering serious mental illness, 
primary care and quality indicators. Full papers were divided into four groups and independently 
reviewed by MG & CO, TD & LA, TK & SG, and RJ & CK. The focus of the selection was to identify 
papers that included relevant quality indicators that could be applied in primary care. It was evident 
that the definition of primary care varies between different countries so we included indicators with 
elements of shared care between primary and specialist settings (e.g. prescribing and monitoring of 
antipsychotic medication), whilst acknowledging that in some countries, those indicators may be 
more applicable to secondary care. 
Our search strategy complied with the PRISMA checklist (see Appendix 2). 
Data Extraction and Analysis 
From each paper a short description of each indicator was extracted, and the descriptions for similar 
indicators were merged. After reviewing the general areas covered by the indicators, they were 
grouped into six domains: (Co-ordination of Care, Substance Misuse, Service Provision and Access to 
Care, Medicines Management, Mental Health Assessment and Care, and Physical Health Assessment 
and Care). The domains were selected by the research team, which included service users, as 
representing broad areas of service provision and care that were viewed as important and could 
encompass all the chosen indicators. Some of the indicators may overlap the domain description 
boundaries as they are not intended to be rigid boundaries. Given the main focus of our study, we 
decided whether each indicator could, in principle, be measured from routine data or whether 
primary data collection would be necessary. Furthermore, we checked whether the identified 
indicators had ever been included in the QOF. We also assessed the quality of the evidence of the 
included studies using an adaptation of the GRADE guidelines 
25
 and rated the quality of the 
evidence as high (systematic reviews or randomised control trials), moderate (non-randomised 
control studies or unsystematic reviews), low (expert opinion or uncontrolled studies) or not 
applicable (measure was extracted from the grey literature). 
Results 
In total 1,847 studies and further database sources were identified using the search. The split was 
ASSIA (34), CENTRAL (96), Cochrane (12), Conferences Proceedings (125), DARE (28), EMBASE (738), 
Ovid Medline (537), PsycINFO (271) and 6 further database sources (AHRQ 
24
, Stegbauer et al 
21
, 
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Gro¡imlinghaus et al 23, Parameswaran et al 22, and NICE 26,27). After removing duplicates using 
bibliographic software (EndNote and Zotero), 1,303 records remained. Title screening reduced this 
to 356, excluding those that were not about quality indicators, or primary care, or mental illness, or 
were not included in our definition of SMI (e.g. depression or substance misuse disorders). Abstract 
screening reduced the records to 113, with similar reasons for exclusion. Finally, from those 113 
records 86 were excluded, and 27 records were included in the review (see PRISMA flow diagram, 
Figure 1). Out of these 27 records, a final set of 59 different indicators was extracted. See Table 1 for 
the final list of indicators. 
[Figure 1 about here] 
[Table 1 about here] 
Table 1 shows that of the 59 indicators, 53 could potentially be assessed using routine data and 
seven would require primary data collection from patients or professionals. Seventeen of the 59 
indicators are, or have previously been included in the QOF. A large proportion of the indicators 
relevant to primary care are in the physical health domain. Another large sub-set of indicators relate 
to the process of receiving care, for example, continuity of care, access to services and frequency of 
contacts. 
Table 2 shows the quality of evidence of the included studies from which the indicators were drawn. 
Four studies were rated as high quality (Cochrane or systematic review, randomised control trial); 
two as moderate (non-randomised study or unsystematic review); 19 as low quality (expert opinion, 
uncontrolled studies); and four were of uncertain quality, having been identified from ƚŚĞ  ?grey ? 
literature (e.g. (non- ?ŐŽǀĞƌŶŵĞŶƚŽƌŐĂŶŝƐĂƚŝŽŶƐ ?ĚŽĐƵŵĞŶƚƐŽƌĚĂƚĂďĂƐĞƐ).  
Only very few randomised control trials (RCTs) have evaluated quality indicators. Two RCTs were 
reviewed in Cimo et al 
29
 producing evidence on the effectiveness of lifestyle interventions for 
people with type 2 diabetes and schizophrenia or schizoaffective disorder. However, more often, 
indicators were based on expert consensus or small cross-sectional studies. 
Many of the indicators identified were derived from a database of indicators produced by the USA 
Agency for Healthcare Research and Quality (AHRQ) 
24
, and the strength of evidence underpinning 
the individual indicators is variable.  
[Table 2 about here] 
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Discussion 
Summary 
To our knowledge this is the first attempt to identify potential indicators of quality of primary care 
for people with SMI in a systematic way. Although we identify over 50 indicators which could 
potentially be captured and monitored using routine data, crucially, we note that the quality of the 
available evidence underpinning the indicators is relatively weak. 
Strengths and limitations 
The feasibility of collecting data for any set of quality indicators will vary across different healthcare 
systems. Many countries have insurance or other systems, which routinely collect activity data in 
primary care. Some indicators are likely to require more effort to collect (e.g. patient questionnaires 
for perceived continuity of care) and in many cases even routine data collection can prove very 
challenging. Our study focused specifically on finding indicators which could be monitored at 
relatively low cost to the healthcare system. 
The list of quality indicators identified in this study is much broader and more encompassing than 
the current list of indicators contained in the QOF SMI domain. However, some of the criticisms 
inherent to the use of quality metrics would remain even if indicators from this broader list were 
adopted. These include: measuring only what can be measured (in routine data) at the expense of 
other measures that matter, Ğ ?Ő ? ?ƐŽĨƚĞƌ ?ŵĞĂƐƵƌĞƐƐƵĐŚĂƐƚŚĞƋƵĂůŝƚǇŽĨƌĞůĂƚŝŽŶƐŚŝƉƐŽƌƚŚĞƋƵĂůŝƚǇ
of communication 
30
; the risk of prioritising some activities at the expense of other non-incentivised 
activities 
31,32
; and the wider impacts of financial incentives and excessive measurement on provider 
motivation and behaviour 
33
. Moreover, there are gaps in the literature and in the indicators 
identified, meaning that the service user perspective is not well represented. There is also an 
absence of quality indicators around aspects of the social environment, such as the stability of 
housing for people with SMI. Although such factors are important and may well influence health 
outcomes, the extent to which primary care could influence these factors may be very limited and 
hence it may not be appropriate to hold primary care practitioners responsible for improving quality 
in these domains. We also acknowledge that there is an extensive literature in related areas of 
research that will also refer to very similar quality indicators 
34
, but the search terms were designed 
to focus on our specific area of interest, and screened out studies where the focus was broader. 
Finally, our search excluded non-published indicators and those written in languages other than 
those listed earlier. 
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Implications for Research and/or Practice 
In the UK, to be included in the QOF, quality indicators must be supported by NICE evidence-based 
clinical guideline recommendations or evidence from systematic reviews. This, along with the need 
to maintain a manageable panel of indicators, explains why the large majority of indicators we 
identified are not currently part of the QOF. The downside of the QOF approach is that 
recommendations based on expert consensus are not put forward for inclusion, despite the fact that 
a body of informed experts would support a prima facie rationale for including them. In contrast, the 
combined views of experts and patients underpin best practice guidance for those commissioning 
mental health services in the UK, covering many of the domains identified in this review, suggesting 
scope for a similar approach to be taken with respect to the QOF 
35
. The adoption of indicators based 
on expert and patient consensus must ultimately be supported by evidence on cost-effectiveness, 
but this also applies to indicators based on higher levels of evidence 
36
. 
ŽŶĂďĞĚŝĂŶ ?Ɛ37 conceptual framework of quality of care suggests indicators can usually be divided 
into three subcategories: structure, process and outcome measures. To date, the evidence for 
apparent process improvements under incentive schemes leading to improved patient outcomes is 
mixed. The vast majority of indicators included in this review relate to processes of care, and whilst 
aspects of process are highly relevant, especially to patients, it is important to establish whether 
quality indicators also promote improved health outcomes. If so, there is a case for their inclusion in 
the QOF and other initiatives aiming to improve the care of people with SMI. For physical conditions, 
improvements in processes of care in primary care settings have been found to be associated with 
modest improvements in intermediate outcomes (e.g. cholesterol levels) 
38
 and quality of life 
39
,
 
but 
associations with patient outcomes such as emergency hospital admission are weaker 
40
. For serious 
mental illness, the evidence is much more limited and suggests that higher provider performance on 
processes may not be associated with better patient outcomes 
17
. 
Many of the indicators identified in the study relate to aspects of physical care.  People with SMI are 
at higher risk of physical ill health (particularly diabetes, cardiovascular and respiratory disease), so 
clearly focusing on these aspects could help reduce the associated excess morbidity and mortality 
28
.   
People with SMI are vulnerable with significant needs for care that may be missed or undertreated, 
leading to years spent with disabling morbidity and premature mortality. Viron et al 
14
 emphasised 
that in the USA, as elsewhere,  ?As frontline clinicians, primary care providers have the potential to 
ƌĞĚƵĐĞƚŚĞŚĞĂůƚŚĚŝƐƉĂƌŝƚŝĞƐĞǆƉĞƌŝĞŶĐĞĚďǇƚŚŝƐƉŽƉƵůĂƚŝŽŶ ?. Consideration of the use of a broader 
set of quality indicators, including those focusing on physical care, may therefore be a positive step. 
Given the increased risk of diabetes, cardiovascular disease and respiratory disease in this 
population, ongoing primary care for people with SMI should focus on disease prevention through 
10 
 
tackling obesity and smoking. Similarly, a large set of indicators relate to processes of care, including 
ongoing contact with relevant services. Targeting comprehensive primary care to people with SMI 
can also play a crucial role in promoting their engagement with appropriate specialised mental and 
physical healthcare services, helping them to reach their full potential. 
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Table 1: Quality of care indicators identified for people with serious mental illness  
Number Description Data Source QOF AHRQ References 
 Co-ordination of Care   
1 Co-ordinated care - identify key worker 
(social worker or CPN) 
Routine 
Data 
  
41 
2 Staff continuity  ? good communication 
between staff and infrequent staff 
changes  
Routine 
Data 
  
42 
3 Continuity: CONNECT is a patient 
questionnaire with 72 items, each rated 
on a 5-point scale, with 13 scales and 1 
single-item indicator (General 
Coordination - "Overall is your Mental 
Health treatment well-coordinated?"). 
Primary Care scales - "How often is 
psychiatrist in contact with your primary 
care doctor?" (Never, Rarely, 
Sometimes, Often, Always). 
Primary 
Data 
  
43 
4 Total number of follow-up contacts 
during treatment episode after initial 
evaluation 
Routine 
Data 
  
44 
 Substance Misuse  
 
5 Patients with SMI who smoke who are 
offered tobacco counselling / help to 
stop smoking 
Routine 
Data 
  
24,27 
6 Alcohol misuse screening Routine 
Data 
9 9 24 
7 Screening for illicit drug use, type, 
quantity and frequency 
Routine 
Data 
 9 24 
8 Referral to substance misuse disorder 
specialty care if appropriate 
Routine 
Data 
  
22 
9 HIV screening with co-occurring 
substance misuse for SMI service users 
Routine 
Data 
  
45 
 Service Provision and Access to Care  
 
10 Practice can produce register of all SMI 
patients 
Routine 
Data 
9  46 
11 Service user registration with a primary 
health organization 
Routine 
Data 
  
22 
12 Markers of care recorded: Contact with 
secondary health services, written care 
plans, 6-month mental health review, 
identified care coordinator, evidence of 
physical examination 
Routine 
Data 
9  47 
13 Patients who do not attend the practice 
for their annual review who are 
identified and followed up by the 
practice team 
Routine 
Data 
9 9 24 
14 System contact: Number of patients in 
contact with the treatment system 
Routine 
Data 
  
22 
12 
 
15 Surveillance to prevent relapse Routine 
Data 
  
42 
16 Crisis management and out of hours 
services 
Routine 
Data 
  
43 
17 Access to services and range of services Routine 
Data 
  
42 
18 Family care - record of families living 
with person with schizophrenia 
Primary 
Data 
  
41 
19 Duration of untreated psychosis: 
Number of recently diagnosed patients 
Routine 
Data 
  
22,48 
20 Waiting time between registration and 
start of treatment 
Routine 
Data 
  
22 
 Medicines Management  
 
21 All current medication clearly available 
at all consultations - known drug 
dosages, frequencies, history of side 
effects, review date 
Primary 
Data 
  
41 
22 Monitor patients suffering extra 
pyramidal effects, check compliance 
Routine 
Data 
  
49 
23 Assess weight gain, use of concomitant 
medication 
Routine 
Data 
9  50 
24 Use of lithium: Plasma lithium levels 
monitored regularly 
Routine 
Data 
9  26,51 
25 Percentages of bipolar service users 
prescribed antidepressants and 
anxiolytics 
Routine 
Data 
  
26,51 
26 Proportion of patients who are 
receiving depot antipsychotics who 
have appropriate laboratory screening 
tests 
Routine 
Data 
 9 24 
27 Patients have their antipsychotic 
medication reviewed regularly, 
considering symptoms and side effects: 
Appropriate referral to specialist 
Routine 
Data 
  
52,53 
28 Polypharmacy: Reduce number of 
patients using more than four 
psychotropic drugs at the same time 
Routine 
Data 
  
54 
29 Monitoring patients with neurological, 
sexual, sleeping and sedation side 
effects 
Routine 
Data 
  
55 
 Mental Health Assessment and Care  
 
30 Percentage of patients given annual 
mental health review by GP 
Routine 
Data 
9  56 
31 Comprehensive mental status 
examination and history conducted in 
patients with a new treatment episode 
Routine 
Data 
 9 24,41 
32 Referral for specialist mental health 
assessment 
Routine 
Data 
  
26 
33 Comprehensive assessment of co-
morbid psychiatric conditions and 
Routine 
Data 
 9 24 
13 
 
response to treatment 
34 Reassess severity of symptoms Routine 
Data 
9  57 
35 Examined for duration of untreated 
psychosis 
Primary 
Data 
  
48 
36 Delayed diagnosis Primary 
Data 
  
58 
37 Informal carer contacts Primary 
Data 
  
42 
38 Information on employment status Primary 
Data 
  
41 
 Physical Health Assessment and Care  
 
39 Diabetes monitoring for people with 
diabetes and schizophrenia 
Routine 
Data 
 9 24 
40 Diabetes and cholesterol monitoring for 
people with schizophrenia and diabetes 
Routine 
Data 
 9 24 
41 Diabetes screening for people who are 
using antipsychotic medications 
Routine 
Data 
 9 24 
42 Blood pressure screening for patients 
with diabetes 
Routine 
Data 
9 9 24,59-62 
43 Weight management / BMI monitoring  Routine 
Data 
9 9 24,59-62 
44 Proportion with increased BMI / 
abdominal waistline 
Routine 
Data 
9 9 24,59-62 
45 Patients with diabetes who received 
education about diabetes, nutrition, 
cooking, physical activity, or exercise 
Routine 
Data 
 9 24 
46 Counselling on physical activity and / or 
nutrition for those with documented 
elevated BMI 
Routine 
Data 
9 9 24 
47 Retinal exam for SMI patients who have 
diabetes 
Routine 
Data 
 9 24 
48 Foot exam for SMI patients who have 
diabetes 
Routine 
Data 
 9 24 
49 Hypertension counselling: Patients with 
hypertension who received education 
services related to hypertension, 
nutrition, cooking, physical activity, or 
exercise 
Routine 
Data 
 9 24 
50 Hypertension: Recording and 
monitoring patients with hypertension 
and high blood cholesterol (LDL) 
Routine 
Data 
9 9 24,59-62 
51 Breast cancer screening for women Routine 
Data 
 9 24 
52 Colorectal cancer screening Routine 
Data 
 9 24 
53 Proportion patients who have an 
increased blood pressure 
Routine 
Data 
9 9 24,59-62 
54 Proportion of patients who have an Routine 9 9 24 
14 
 
increased blood glucose level Data 
55 Proportion of patients who have low 
levels of glycosylated haemoglobin 
Routine 
Data 
9 9 24 
56 Proportion of patients who have 
increased level of blood lipids 
Routine 
Data 
  
21 
57 Comprehensive physical health 
assessment with appropriate advice 
Routine 
Data 
9  57 
58 Patients with diabetes who received 
psychoeducation related to weight 
(BMI), diabetes (blood glucose levels) 
Routine 
Data 
  
29 
59 Medical attention for nephropathy Routine 
Data 
  
63 
Note: QOF = UK Quality Outcomes Framework; AHRQ = Agency for Healthcare Research & Quality; BMI = Body Mass Index; LDL = Low-
density lipoprotein; GP = General practitioner; CPN = Community psychiatric nurse; SMI = Serious mental illness  
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Table 2: Quality of evidence of studies identifying quality of care indicators for people with serious 
mental illness  
Study Description of Study 
Strength of 
Evidence* 
Parameswaran, Spaeth-
Rublee, Pincus 
22
 
656 measures of quality of mental health care identified 
in earlier work are rated in importance, validity and 
feasibility using a modified Delphi process. 
3 
National Institute for 
Health and Care 
Excellence (NICE) 
26
 
NICE treatment guidelines for bipolar disorder. 4 
National Institute for 
Health and Care 
Excellence (NICE) 
27
 
NICE treatment guidelines for schizophrenia. 4 
Agency for Healthcare 
Research and Quality 
(AHRQ) 
24
 
The Agency for Healthcare Research and Quality provides 
a database of quality indicators that was used during the 
grey literature search. 
4 
Lester, Tritter, Sorohan 
46
 Focus groups with patients, GPs and nurses were 
conducted to explore how to improve care in cases of 
acute mental health crises. 
3 
Sweeney, Rose, Clement, 
Jichi, Jones, Burns, Catty, 
McLaren, Wykes 
42
 
Structured interviews were conducted with 167 
individuals suffering from psychoses to establish a 
concept of service user-defined continuity of care. 
3 
Ware, Dickey, Tugenberg, 
McHorney 
43
 
This study reports on the field testing of an interview 
based measure of continuity of care. 
3 
Cerimele, Chan, 
Chwastiak, Avery, Katon, 
Unützer 
44
 
Narrative description of 740 bipolar primary care patients 
who participated in a mental health integration program 
(MHIP). Quality of care outcomes were derived from 
patient disease registry. 
3 
Pincus, Spaeth-Rublee, 
Watkins 
57
 
Discussion on the barriers to measuring quality of care in 
the mental health arena combined with a short list of 
potential quality measures. 
3 
Holden 
41
 This study audited 16 GPs on their care for 266 
schizophrenia patients and observed that the audit lead 
to improved recording of a range of quality indicators. 
3 
Swartz, MacGregor 
45
 The authors of this paper argue that in South Africa the 
role of mental health nurses has been altered to focus on 
violence, substance misuse and HIV/AIDS and should be 
refocused on psychiatry care in the primary care setting. 
3 
Ruud 
48
 The author summarizes the literature on quality of care 
in mental health services in Norway for the years 2008-
2009. 
3 
Highet, McNair, 
Thompson, Davenport, 
Hickie 
58
 
Interviews with 49 bipolar patients to describe 
experience in primary care in Australia. Eight themes for 
improvement of the primary care experience are 
outlined.  
3 
Lader 
49
 Expert review of the standards of care in schizophrenia to 
reduce side-effects whilst achieving best treatment 
outcomes. 
3 
Haro, Salvador-Carulla 
50
 Observational study following eleven thousand patients 
who were on or changing antipsychotic medication to 
2 
16 
 
determine the best course of treatment with respect to 
symptoms, quality of life, social functioning and other 
outcomes. 
Caughey, Ellett, Wong 
51
 Development, expert review, and assessment of the 
evidence base for and validity of medication-related 
indicators of potentially preventable hospitalisations. 
3 
Busch, Lehman, 
Goldman, Frank 
52
 
Observational study examining trends in four measures 
of quality over time in the US. 
2 
Young, Sullivan, Burnam, 
Brook 
53
 
Uncontrolled study looking at differences in quality of 
care as variations from national guidelines. 
3 
Nayrouz, Ploumaki, 
Farooq, Stock, Lim 
54
 
Evaluation of an integrated care approach between 
primary care and community care focused on SMI 
patients. 
3 
McCullagh, Morley, 
Dodwell 
47
 
This observational study looks at urban vs rural 
differences in quality of care for psychoses as well as the 
difference in quality of care conditional on contacts with 
secondary care. 
3 
Rodgers, Black, Stobbart, 
Foster 
56
 
Audit of quality of care in 822 Scottish patients with 
schizophrenia. 
3 
Osborn, Nazareth, 
Wright, King 
59
 
Randomised trial to evaluate the impact of a nurse-led 
treatment to improve screening for CVD in the SMI 
population. 
1 
Yeomans, Dale, Beedle 
60
 Evaluation of a computer-based physical health screening 
template versus NICE guidelines for the SMI population. 
3 
Mitchell, Delaffon, Lord 
61
 A systematic review and meta-analysis of screening 
practices with respect to metabolic risks for psychosis 
patients. 
1 
Roberts, Roalfe, Wilson, 
Lester 
62
 
A retrospective view of case notes in 22 GP practices to 
determine whether patients with schizophrenia receive 
equitable physical health care. 
3 
Mainz, Hansen, Palshof, 
Bartels 
55
 
Description of the Danish National Indicator Project, 
which intends to document and advance quality of care. 
3 
Druss, Zhao, Cummings, 
Shim, Rust, Marcus 
63
 
The study compared diabetes performance measures in 
US Medicaid enrolees with and without mental 
comorbidity. 
2 
*Quality of evidence 
25
 is categorised as (1) High  ? Cochrane or systematic review, randomised 
control trial; (2) Moderate  ? non-randomised control study or unsystematic review; (3) Low  ? expert 
opinion, uncontrolled studies; (4) Not applicable  ? measure was extracted from grey literature e.g. 
(non- ?ŐŽǀĞƌŶŵĞŶƚŽƌŐĂŶŝƐĂƚŝŽŶƐ ?ĚŽĐƵŵĞŶƚƐŽƌĚĂƚĂďĂƐĞƐ 
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Figure 1: PRISMA 
58
 Flow Diagram for systematic review of quality of care 
indicators for patients with serious mental illness 
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Appendix 1 - Annotated search strategy: (MEDLINE via OVID SP) 
1     serious mental illness*.tw. (2037) 
2     serious mental disorder*.tw. (260) 
3     serious psychiatric illness*.tw. (61) 
4     serious psychiatric ill-health*.tw. (0) 
5     serious mental ill-health*.tw. (0) 
6     serious psychiatric disorder*.tw. (130) 
7     severe mental illness*.tw. (2679) 
8     severe mental disorder*.tw. (720) 
9     severe mental ill-health*.tw. (2) 
10     severe psychiatric illness*.tw. (128) 
11     severe psychiatric disorder*.tw. (379) 
12     severe psychiatric ill-health*.tw. (0) 
13     major mental disorder*.tw. (288) 
14     major mental illness*.tw. (350) 
15     major psychiatric illness*.tw. (151) 
16     major psychiatric ill-health*.tw. (0) 
17     major psychiatric disorder*.tw. (730) 
18     major mental ill-health*.tw. (0) 
19     schizophrenia/ or schizophrenia, 
catatonic/ or schizophrenia, disorganized/ or 
schizophrenia, paranoid/ or shared paranoid 
disorder/ (86432) 
20     (Schizophrenia* or schizophrenic or 
dementia praecox).tw. (90771) 
21     Schizotypal Personality Disorder/ (2217) 
22     (disorder* adj2 schizotypal).tw. (702) 
23     (disorder* adj1 delusional).tw. (703) 
24     Psychotic Disorders/ (32708) 
25     ((psychotic adj2 disorder*) or 
(schizoaffective adj2 disorder*) or psychoses 
or psychosis or schizophreniform).tw. (38127) 
26     bipolar disorder/ or cyclothymic 
disorder/ (32171) 
27     (Bipolar adj2 (disorder* or depression or 
depressive or psychosis or psychoses)).tw. 
(22038) 
28     (Manic state* or mania).tw. (8053) 
29     (Manic adj2 (disorder* or depression or 
depressive or psychosis or psychoses)).tw. 
(4445) 
30     (cyclothymic disorder* or cyclothymic 
personalities or cyclothymic personality).tw. 
(95) 
31     or/1-30 (179930) 
Line 31 captures terms for serious mental 
illness 
32     exp Primary Health Care/ (82203) 
33     general practitioners/ or physicians, 
family/ or physicians, primary care/ (18403) 
34     general practice/ or family practice/ 
(64455) 
35     (family adj2 pract*).tw. (11764) 
36     (primary adj2 care).tw. (89376) 
37     (general adj2 pract*).tw. (69034) 
38     (family adj2 physician*).tw. (12969) 
39     Ambulatory Care/ (36401) 
40     or/32-39 (268786) 
Line 40 captures terms for primary care 
41     Quality Indicators, Health Care/ (10737) 
42     (quality adj2 indicat*).tw. (6747) 
43     (quality adj2 measure*).tw. (12491) 
44     (quality adj2 criteria).tw. (3829) 
45     (performance adj2 indicat*).tw. (4837) 
46     (performance adj2 measure*).tw. 
(14194) 
47     (performance adj2 criteria).tw. (1367) 
23 
 
48     (incentive* adj3 scheme*).tw. (207) 
49     (incentive* adj3 assess*).tw. (96) 
50     (incentive* adj3 measure*).tw. (152) 
51     (incentive* adj3 outcome*).tw. (96) 
52     "Standard of Care"/ (1049) 
53     (standard* adj2 care).tw. (25676) 
54     (standard* adj2 healthcare).tw. (400) 
55     "Quality of Health Care"/ (58460) 
56     (quality adj2 (healthcare or care)).tw. 
(39007) 
57     patient outcome assessment/ (934) 
58     (patient adj2 outcome assessment*).tw. 
(70) 
59     (patient adj2 outcome measure*).tw. 
(2492) 
60     proms.tw. (263) 
61     patient satisfaction/ or patient 
preference/ (63756) 
62     (patient* adj2 satisfaction).tw. (26024) 
63     (patient* adj2 experience*).tw. (59692) 
64     (patient* adj2 preference*).tw. (8103) 
65     quality.tw. (594390) 
66     or/41-65 (782974) 
Line 66 captures terms for quality indicators 
67     31 and 40 and 66 (551) 
Line 67 identifies records that contain at 
least one term for serious mental illness, and 
at least one term for primary care and at 
least one term for quality indicators 
68     limit 67 to yr="1990 -Current" (537) 
Line 68 applies the date limit 
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Appendix 2:  PRISMA Checklist 
64
 for systematic review of quality of care indicators for patients with serious mental illness 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  3 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
N/A 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
16 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
4 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
4 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
4 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
N/A 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  N/A 
25 
 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
N/A 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
5 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
8 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  N/A 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
N/A 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
N/A 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
5 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
6 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
6 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
1 
 
 
